Advertisement
Product › Details
Zinnat®
Next higher product group | cefuroxime (INN) | |
Status | 1989-01-01 registration start | |
Status | 1998-01-01 sales existent | |
Record changed: 2023-07-10 |
Advertisement
More documents for anti-infective drug
- [1] Precisio Biotix Therapeutics, Inc.. (3/1/24). "Press Release: Precisio Biotix Therapeutics Acquires London-headquartered CC Bio, Adding World-class Antibacterial Platform and Top Scientists". Dover, DE....
- [2] Antabio SAS. (12/12/23). "Press Release: Antabio Raises €25 Million in Series B Financing". Labège....
- [3] Exscientia plc. (12/5/23). "Press Release: Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza". Oxford....
- [4] Glox Therapeutics Ltd.. (11/14/23). "Press Release: Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria". Glasgow....
- [5] Memo Therapeutics AG. (11/02/23). "Press Release: Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients". Schlieren....
- [6] LimmaTech Biologics AG. (10/9/23). "Press Release: LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections". Schlieren....
- [7] Atriva Therapeutics GmbH. (11/9/22). "Press Release: Atriva Therapeutics Appoints Christian Pangratz as Chief Executive Officer, Implementing Planned Management Change". Tübingen, Frankfurt a.M. & Martinsried....
- [8] GSK plc. (9/22/22). "Press Release: GSK and Spero Therapeutics Announce Exclusive Licence Agreement for tebipenem HBr, a Late-stage Antibiotic that May Treat Complicated Urinary Tract Infections". London....
- [9] F2G Ltd.. (8/4/22). "Press Release: F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim". Manchester....
- [10] Synklino ApS. (6/8/22). "Press Release: Synklino Completes Series A Raise of EUR 29.8 Million to Advance Clinical Trials of Its Drug Candidate for the Treatment of Cytomegalovirus (CMV)". Copenhagen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top